Reshma Kewalramani, CEO & President at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 40,000 shares at $479.75 ($19.7M) on 2026-02-27, disclosed to the SEC on 2026-03-03.
Open-market sale of $19.7M VRTX by CEO & President. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $479.75 | 400 | $192K | 1.0% |
| 2 | $481.50 | 120 | $58K | 0.3% |
| 3 | $482.84 | 240 | $116K | 0.6% |
| 4 | $487.13 | 2,510 | $1.2M | 6.2% |
| 5 | $488.27 | 3,278 | $1.6M | 8.1% |
| 6 | $489.32 | 460 |
| $225K |
| 1.1% |
| 7 | $490.54 | 2,725 | $1.3M | 6.8% |
| 8 | $491.30 | 949 | $466K | 2.4% |
| 9 | $493.29 | 2,520 | $1.2M | 6.3% |
| 10 | $494.33 | 3,498 | $1.7M | 8.8% |
| 11 | $495.38 | 15,580 | $7.7M | 39.1% |
| 12 | $496.16 | 5,995 | $3.0M | 15.1% |
| 13 | $496.95 | 1,725 | $857K | 4.3% |
| Total | $493.47 avg | 40,000 | $19.7M | 100% |
| Filing → |
| VRTX | SELL | 2024-08-01 | $7.7M | — | Filing → |
| VRTX | SELL | 2024-07-24 | $7.6M | — | Filing → |
| VRTX | SELL | 2024-05-29 | $715K | — | Filing → |